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Abstract
Objective: To assess differences in body circumferences and body mass index (BMI, kg/m2) between antiretroviral treatment
(ART) naı¨ve HIV-infected and HIV-uninfected persons.
Methods: Waist, arm, and thigh circumferences and BMI were measured within the ALLRT and NHANES cohorts between
1998 and 2007. ALLRT is a prospective, longitudinal study of U.S. participants enrolled in randomized HIV treatment studies
conducted by the AIDS Clinical Trials Group (ACTG). NHANES is a representative group of the US population. The cohorts
were analyzed in two time periods, to account for trends towards increased adiposity. Anthropometrics were displayed in
percentiles by age and sex. Multiple linear regression models examined differences between cohorts.
Results: ALLRT had more males (82% versus 48%, p,0.0001), more black participants (32% versus 23%, p,0.0001), and less
Hispanics (21% versus 30%, p,0.0001) than NHANES. Mean BMI was smaller in ALLRT males and females compared to
NHANES by 1.6–2.4 kg/m2 (p,0.0001). Mean waist and arm circumferences in both sexes and time periods were
significantly smaller in ALLRT than in NHANES (p,0.0001). Mean thigh circumference in ALLRT was also smaller than
NHANES among males (p,0.0001 in both time periods) and females (p = 0.01 in the early time period).
Conclusions: Differences in anthropometrics existed prior to ART initiation, in this large national cohort of HIV-infected
individuals, compared to a representative HIV-uninfected cohort, indicating that HIV and its complications have important
effects on body shape. Further longitudinal examination of anthropometrics in this HIV-infected cohort may provide
additional insight into disease risk.
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Introduction
Weight distribution plays an important role in disease risk and
mortality. Abdominal obesity, defined as waist circumference
(WC) $102 cm for men and $88 cm for women, increased in the
United States between 1999 and 2008 for both sexes [1]. Obesity,
or body mass index (BMI) $30 kg/m2, also increased for both
sexes over the same time period. In a 10-year longitudinal study of
over 100,000 U.S adults over the age of 50, elevated waist
circumference predicted increased all-cause, cancer-related, and
cardiovascular mortality [2]. BMI also predicted all-cause, cancer-
related, and cardiovascular mortality in a cohort of over 1 million
mostly-white volunteers in the U.S., with increased risk in the
overweight (BMI 25 to,30 kg/m2), obese, and underweight (BMI
,18.5 kg/m2) subjects compared with healthy weight (BMI 18.5
to ,25 kg/m2) [3]. Thus, weight distribution and body shape are
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associated with overall death rates, as well as those from cancer
and cardiovascular disease.
Lipodystrophy (peripheral fat loss and/or central fat gain) is a
common diagnosis in HIV-infected individuals; and similar to
general or abdominal obesity, is an altered distribution of body fat.
Between 13% and 62% of HIV-infected persons have been
reported to develop lipodystrophy [4–6]. Self-report, case diagno-
sis, and assessment by clinicians are used to diagnose lipodystrophy
and its components, although imaging studies are also used as
research tools [5–7]. Body weight and circumferences correlate
well with regional body compositions measured by dual-energy x-
ray absorptiometry (DXA) in HIV-infected subjects both naı¨ve to
antiretroviral therapy (ART) and during ART [8].
Lipodystrophy negatively affects many aspects of health in
people living with HIV. When matched by age, sex, and BMI with
HIV-uninfected subjects in the Framingham Offspring Study,
Hadigan, et al. reported that male HIV-infected subjects with
clinician-diagnosed lipodystrophy had ten-year coronary heart
disease (CHD) risk that was significantly higher than controls [9].
In the Fat Redistribution and Metabolic change study (FRAM),
elevated WC was positively associated with mortality after 5 years
in 922 subjects [10]. Mean depression scores from 250 patients in
an urban HIV clinic were significantly higher in those with
moderate-to-severe lipoatrophy or with any degree of lipohyper-
trophy, than subjects without lipodystrophy, after controlling for
age, race, sex, drug use, current ART use, and CD4 cell count
[11]. In an Italian metabolic clinic, 401 HIV-infected individuals
were found to have significant reductions in health-related quality
of life with more severe patient-reported lipodystrophy [12]. These
data demonstrate that both aspects of lipodystrophy significantly
impact the physical and mental health of HIV-infected patients.
Alterations in body weight also have a negative influence on the
health of HIV-infected individuals. The Nutrition for Healthy
Living (NFHL) cohort, a group of HIV-infected individuals
enrolled between 1995–2005 in the Northeast U.S., of whom
66% were taking ART, documented that 18% of its enrollees
developed wasting, defined as greater than 10% weight loss [13]. A
study of a managed care population reported greater clinic visits
and doubling of annual health care costs related to HIV-associated
weight loss [14]. Analyses of a HIV-infected military cohort,
between 1996 and 2008, emphasized the importance of a healthy
weight or overweight status, adjusted for time on ART. These
ranges were associated with greater mean increases in CD4
lymphocyte counts, compared to obese or underweight subjects
[15]. In ART-naı¨ve patients at an outpatient clinic in Nashville,
Tennessee, CD4 lymphocyte count increased most after 12
months of ART in those with a baseline BMI between 25–
30 kg/m2 [16]. Thus, normal or overweight BMI appears to have
positive benefits in reduced health care costs and greater immune
reconstitution in HIV-infected individuals.
The aim of this study was to compare anthropometric
measurements during similar time periods in a large group of
HIV-infected, ART-naı¨ve adults of both sexes to HIV-uninfected
men and women. We hypothesized that HIV-infected males and
females would have smaller body circumferences and BMI than
the HIV-uninfected persons.
Methods
Ethics Statement
Subjects (or their parent or legal guardian if they were a minor)
provided written informed consent and institutional review board
(IRB) approval for ALLRT (AIDS Clinical Trials Group (ACTG)
Longitudinal Linked Randomized Trials) was obtained by each
site.
Study Population
HIV-Infected individuals. ALLRT is a prospective, longi-
tudinal, observational cohort of U.S. adults enrolled in random-
ized HIV treatment studies (parent studies) conducted by the
ACTG. The study design and rationale of ALLRT have been
previously described [17]. After completion of their parent study,
participants in ALLRT continue in long-term follow-up. This
study utilized data from six ALLRT parent studies that enrolled
participants who were ARV-naı¨ve [18–23].
HIV-Uninfected individuals. We used data from the
National Health and Nutrition Examination Survey (NHANES)
from 1999 to 2006. NHANES is a national survey of the U.S.
population conducted annually which focuses on health and
nutritional status, using interviews and physical exams. Additional
details about NHANES can be found elsewhere [24]. HIV
antibody test results were available in NHANES for approximately
60% of subjects aged 18–49 years who didn’t refuse the test; only
0.6% were positive. Given the small proportion of HIV-infected
participants, these subjects were not excluded from our analyses of
NHANES data. Only data from NHANES subjects aged 17–74
years were included to match the age range of participants in
ALLRT. NHANES race/ethnicity definitions of ‘Mexican-Amer-
ican’ and ‘Other Hispanics’ were collapsed into a category of
‘Hispanic’ to correspond to the definitions used in ALLRT.
Data Collection
HIV-Infected individuals. Data collection for ALLRT at
each visit (every 16 weeks) includes medical and medication
history, weight, and vital signs. Height is measured at parent trial
entry. Measurements of waist circumference (WC), arm circum-
ference (AC) and thigh circumference (TC) were initially measured
at parent trial entry (baseline) prior to ART initiation, and then
every 48 weeks thereafter. For some individuals, the first available
anthropometric measurement was 16 weeks after baseline due to
the timing of their ALLRT entry visit. For these individuals, the
anthropometric measure at week 16 was considered as baseline.
Anthropometrics among ALLRT participants outside of pre-
determined extreme ranges were not included (body weights had
to be between 23–182 kg, WC between 61–160 cm, AC between
18–51 cm, and height between 120–213 cm).
HIV-Uninfected individuals. NHANES participants com-
pleted an interview and standardized medical exams. Anthropo-
metric evaluations included height, weight, WC, AC, and TC
[24]. NHANES data are available continuously from 1999 to the
present and datasets in 2-year intervals are available to the public
on the Centers for Disease Control (CDC) website [25]. We used
data from the NHANES years closest to the enrollment years for
the ALLRT cohort. To account for increases in body weight and
WC in the U.S. population over time [1], we divided the
NHANES and ALLRT subjects into two groups: those enrolled in
1999–2002 and 2003–2006 for NHANES, and 1998–2002 and
2003–2007 for ALLRT. NHANES checks for measurement and
recording errors at the 1st and 99th percentiles of anthropometric
data, based on NHANES III reference values, and excludes data
from its datasets thought to be erroneous [26]. Ten percent of
NHANES participants with any missing anthropometric measures
were excluded.
Data Analysis
Categorical variables were compared between ALLRT and
NHANES using chi-square tests. Continuous variables were
Anthropometrics in HIV: 1998–2007
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compared using the Wilcoxon test. Summaries of BMI and
anthropometric measures by sex and age were presented using
percentiles. The prevalence of BMI #20 kg/m2 was reported, as
this cut-off predicts increased mortality in HIV-uninfected
populations [3], and has been used to indicate wasting in HIV-
infected populations [27]. To compare anthropometric measures
between ALLRT and NHANES subjects of the same sex, equality
of means was tested using linear regression, adjusting for age,
race/ethnicity, square root of height (!height ), diabetes history
and smoking history. The inclusion of !height in regression
analyses accounts for body circumference differences noted
between short and tall adults within ethnicities and age groups,
as noted in a recent analysis of NHANES III [28]. Age and race-
adjusted WC and hip circumference measures, in this represen-
tative population, scaled to height with powers between 0.45 and
0.8 in men and women, for an average of approximately 0.5–
much different than the height-squared factor included in the
calculation of BMI. For all analyses, p,0.05 was considered
statistically significant.
Results
Demographics of Study Population
A total of 3375 ALLRT and 18,833 NHANES participants
were included in this analysis, as seen in Figure 1. Demographic
characteristics of the ALLRT and NHANES participants during
each of the two periods are presented in Table 1. ALLRT subjects
were more likely to be male (82% and 48% in ALLRT and
NHANES, respectively, p,0.0001). ALLRT enrolled a higher
proportion of black subjects and a smaller proportion of Hispanics
than NHANES in both periods (p,0.0001).
In ALLRT, during the first time period, females and males were
of similar age, but during the second time period, women were
slightly older (median age in years (Q1, Q3) = 38 (31, 45) in males,
40 (33, 46) in females, Wilcoxon test p-value = 0.01). In NHANES,
males were slightly older than females in each time period (median
age in years (Q1, Q3) = 40 (23,56) in males, 37 (24, 54) in females,
Wilcoxon test p-value = 0.02 in the first time period) (median age
in years (Q1, Q3) = 39 (24, 55) in males and 36 (24, 53) in females,
Wilcoxon test p-value = 0.004 in the second time period). Rates of
smoking were significantly higher among ALLRT participants, but
prevalence of diabetes mellitus was significantly lower than in
NHANES (Wilcoxon test p-value,0.0001 in each time period).
Figure 1. Flow diagram. NHANES: National Health and Nutrition Examination Survey ALLRT: AIDS Clinical Trials Group Longitudinal Linked
Randomized Trials.
doi:10.1371/journal.pone.0065306.g001
Anthropometrics in HIV: 1998–2007
PLOS ONE | www.plosone.org 3 June 2013 | Volume 8 | Issue 6 | e65306
Unadjusted Anthropometric Data for HIV-infected
Individuals
The 25th, 50th, and 75th percentiles of unadjusted BMI in
ALLRT are presented in Table 2. The median BMI of younger
males (20–29 and 30–39 years) in both time periods, as well as
older males (40–49 and 50–59 years) in the earlier time period,
was in the healthy BMI range. The median BMI in ALLRT for
females was in the overweight range, with the exception of the
youngest age group in the later time interval that had median BMI
of 24 kg/m2. Within each time period, females had larger BMI
than males (p,0.0001); the differences in medians within age
groups ranged from 0.5–3 kg/m2.
Overall, 4%, 51%, 32%, and 14% of ALLRT participants were
in the underweight, healthy, overweight, and obese BMI
categories, respectively. Two percent, 34%, 33%, and 31% of
NHANES participants fell into these categories. Within the entire
Table 1. Baseline characteristics of the study population.
Baseline Characteristics
ALLRT 1998–2002
(N=1611)
NHANES 1999–2002
(N=9483)
ALLRT 2003–2007
(N=1764)
NHANES 2003–2006
(N=9350)
N (%) N (%) N (%) N (%)
Sex, male 1307 (81) 4550 (48)a 1461 (83) 4494 (48)a
Race/Ethnicity
White, non-Hispanic 731 (45) 3991 (42)a 749 (43) 4182 (45)a
Black, non-Hispanic 500 (31) 2002 (21)a 570 (32) 2301 (25)a
Hispanic 340 (21) 3139 (33)a 385 (22) 2457 (26)a
Other 40 (3) 351 (4)a 60 (3) 410 (4)a
Cigarette smoking history
Ever smokers 956 (60) 4817 (51)a 966 (56) 4643 (50)a
Never smokers 646 (40) 4545 (48)a 759 (44) 4594 (50)a
Diabetes diagnosis
Yes 48 (3) 758 (8)a 60 (3) 828 (9)a
No 1563 (97) 8721 (92)a 1704 (97) 8516 (91)a
Median (Q1, Q3) Median (Q1, Q3) Median (Q1, Q3) Median (Q1, Q3)
Age, years 37 (31, 43) 39 (24, 55)b 38 (31, 45) 38 (24, 54)c
Height, cm 174 (168, 180) 167 (160, 175)a 174 (168, 180) 168 (161, 175)a
Weight, kg 74 (65, 84) 76 (64, 89)a 75 (66, 86) 77 (65, 91)a
CD4+ T-cells/mm3 215 (67, 369.5) – 217 (74, 325) –
HIV-1 RNA, log10copies/mL 4.9 (4.4, 5.5) – 4.8 (4.4, 5.1) –
aNHANES significantly different from ALLRT (p,0.0001) for the corresponding time period.
bNHANES significantly different from ALLRT (p,0.05) for the corresponding time period.
cNHANES not significantly different from ALLRT (p.0.1) for the corresponding time period.
doi:10.1371/journal.pone.0065306.t001
Table 2. BMI (kg/m2), by sex and age in ALLRT.a (Unadjusted percentiles).
1998–2002 2003–2007
N Percentile N Percentile
Age, years 25th 50th 75th 25th 50th 75th
Male
20–29 220 21.5 23.5 26.0 282 21.0 23.0 25.5
30–39 575 22.0 24.5 27.0 528 22.5 24.5 27.5
40–49 369 22.0 24.5 27.0 441 23.0 25.0 28.0
50–59 104 22.0 23.5 26.7 159 23.0 25.0 28.5
Female
20–29 48 23.2 26.0 30.5 43 21.5 24.0 28.0
30–39 121 22.5 27.0 32.0 106 23.5 27.5 33.5
40–49 87 21.5 25.0 29.0 107 22.5 26.5 32.0
50–59 32 22.2 25.7 29.7 40 22.7 26.2 31.0
aALLRT participants ,20 and .59 years were excluded due to limited sample size.
doi:10.1371/journal.pone.0065306.t002
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ALLRT cohort, 9.4% of participants had a BMI less than 20 kg/
m2. These rates were 9.7% to 9.2% in the earlier and later time
periods, respectively. In the NHANES cohort, the overall
prevalence of BMI less than 20 kg/m2 was 6.7%; 7% in the first
time period, and 6.4% in the second time period.
As shown in Table 3, females in ALLRT had larger median WC
than men in ALLRT in the two younger age ranges (20–29 and
30–39 years); however the differences were not statistically
significant. For both men and women, median WC were larger
(p,0.05) in the two older age groups (40–49 and 50–59 years)
during the later time period compared to the earlier by 1.75 to
5 cm for women and 1.5 cm for men.
Overall median AC (Table 4) was smaller in women than men
in ALLRT (p,0.05) within each time period; the differences in
medians by age groups ranged from 0.8 to 2 cm, with the
exception of no difference in youngest age range in the early time
period. For TC (Table 5), women in ALLRT had larger median
circumferences (p,0.0001) than men in ALLRT in the early time
period; the differences in medians by age groups ranged from 1.7–
5 cm. For the second time period, median thigh circumferences
were higher among females than males (not statistically significant)
for all age groups with the exception of females aged 40–49 years.
Adjusted Anthropometric Data comparing HIV-infected
to HIV-uninfected Individuals
Figure 2 (males) and Figure 3 (females) show the comparison of
mean BMI, WC, AC, and TC, for each time period in ALLRT
and NHANES, adjusted for age, race/ethnicity, !height, diabetes
history and smoking history. Mean BMI was 2.3 kg/m2 and
2.4 kg/m2 smaller (both p,0.0001) in ALLRT compared to
NHANES in males in the early and later time periods,
respectively. Females in ALLRT also had significantly smaller
mean BMI than NHANES in the early and later time periods, by
1.8 kg/m2 and 1.6 kg/m2 (both p,0.0001), respectively. Com-
pared to the first time period, adjusted mean BMI was slightly
higher in ALLRT in the second time period (p = 0.05 for males).
Table 3. Waist circumference (cm), by sex and age in ALLRT.a (Unadjusted percentiles).
1998–2002 2003–2007
N Percentile N Percentile
Age, years 25th 50th 75th 25th 50th 75th
Male
20–29 144 78.0 83.5 88.7 269 77.0 83.0 91.5
30–39 374 80.5 87.0 94.0 504 82.0 87.5 96.0
40–49 248 82.5 88.5 95.0 422 84.0 90.0 97.0
50–59 66 82.0 90.0 96.5 149 85.0 91.5 101.5
Female
20–29 30 78.0 86.0 98.0 42 75.5 83.5 90.0
30–39 77 78.0 90.0 102.0 102 81.0 89.8 104.0
40–49 61 77.5 84.5 94.5 104 82.2 89.5 99.0
50–59 20 82.7 89.0 94.5 38 83.0 90.8 100.5
aALLRT participants ,20 and .59 years were excluded due to limited sample size.
doi:10.1371/journal.pone.0065306.t003
Table 4. Arm circumference (cm), by sex and age in ALLRT.a (Unadjusted percentiles).
1998–2002 2003–2007
N Percentile N Percentile
Age, years 25th 50th 75th 25th 50th 75th
Male
20–29 142 27.5 29.5 32.0 238 27.5 29.5 32.0
30–39 369 28.5 31.0 33.5 404 28.5 31.0 33.5
40–49 244 28.0 31.0 33.0 343 29.0 31.5 33.5
50–59 67 28.0 30.0 32.5 129 28.0 30.5 33.0
Female
20–29 30 26.0 29.5 35.5 30 26.0 28.0 31.0
30–39 78 26.5 30.7 35.0 82 27.5 30.2 35.0
40–49 60 27.0 29.0 31.5 80 26.5 30.5 33.7
50–59 19 26.0 28.0 33.5 29 28.5 29.5 32.5
aALLRT participants ,20 and .59 years were excluded due to limited sample size.
doi:10.1371/journal.pone.0065306.t004
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Table 5. Thigh circumference (cm), by sex and age in ALLRT.a (Unadjusted percentiles).
1998–2002 2003–2007
N Percentile N Percentile
Age, years 25th 50th 75th 25th 50th 75th
Male
20–29 147 46.0 50.0 54.0 72 45.5 50.2 54.5
30–39 412 47.0 51.0 55.0 128 48.5 52.0 56.0
40–49 270 46.0 50.0 53.5 108 48.5 51.5 55.0
50–59 81 44.0 48.0 51.5 32 46.0 51.0 56.7
Female
20–29 31 47.5 55.0 60.0 12 49.7 51.2 60.7
30–39 77 49.5 54.0 59.5 20 49.0 59.2 64.0
40–49 64 46.0 51.7 57.2 26 44.0 49.5 55.0
50–59 27 45.0 50.0 56.0 10 43.5 52.7 60.0
aALLRT participants ,20 and .59 years were excluded due to limited sample size.
doi:10.1371/journal.pone.0065306.t005
Figure 2. Mean (95% CI) anthropometrics among males, adjusted* for age, race, !height, smoking history and diabetes history.
NHANES: National Health and Nutrition Examination Survey ALLRT: AIDS Clinical Trials Group Longitudinal Linked Randomized Trials *Age centered at
40 years; reference for race is white; reference for smoking history is non-smoker; reference for diabetes history is no diabetes history. BMI not
adjusted for !height. a NHANES significantly different from ALLRT (p,0.0001). b Significantly different from 1st time period (p#0.05). c Significantly
different from 1st time period (p#0.0001).
doi:10.1371/journal.pone.0065306.g002
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Similarly, adjusted mean BMI was higher in the second time
period in NHANES (p#0.0001 in males, p = 0.02 in females).
Mean WC was smaller for both sexes in both time periods in
ALLRT compared with NHANES. For both time periods, males
in ALLRT had a 7 cm smaller mean WC than NHANES, and
females had a 4.4 cm smaller mean WC (all p,0.0001). Higher
mean WC in the second time period compared to the first were
seen among males in ALLRT (p#0.05) and both sexes in
NHANES (both p#0.0001).
Mean AC and TC showed the same relationship among both
sexes–significantly smaller circumferences in ALLRT than in
NHANES at each time period. Mean AC was not different
between time periods within ALLRT, but was significantly larger
in the second time period in NHANES (p#0.05). The difference in
TC in females between ALLRT and NHANES was smaller than
in men. For example, in the first time period, males in ALLRT
had TC 3.6 cm smaller than NHANES, and females in ALLRT
were 1.4 cm smaller than NHANES. There was no difference in
the mean TC between time periods within females in ALLRT,
and both sexes in NHANES; however the mean TC among males
in ALLRT was higher in the second time period compared to the
first period (p = 0.001).
Adjustment for BMI instead of !height (Table 6) decreased the
differences in circumferences for waist, arm, and thigh in ALLRT
in both time periods, compared with NHANES. With the
adjustment for BMI, WC was more similar in ALLRT and
NHANES among females in the first time period (p = 0.9), but still
larger in NHANES in the later time period only (p = 0.03). Using
BMI to adjust the data comparing females suggested larger TC in
ALLRT than in NHANES in both time periods with this model in
contrast to the results with !height used to adjust the data.
Discussion
To our knowledge, this is the largest study comparing the
anthropometrics of HIV-infected individuals to the general U.S.
population. An important, but not unexpected finding is that most
anthropometric measures were significantly smaller in this HIV-
infected ALLRT cohort, with advanced HIV disease, prior to the
initiation of ART versus the HIV-uninfected population in
NHANES. Given the temporal increases noted in all anthropo-
metrics, with the exception of TC among females, our use of two
separate time periods is justifiable.
The significance of BMI, body shape changes, and wasting in
HIV care is evolving. Between 1996–2006, the percentage of
deaths as a result of HIV and wasting/cachexia, fell from 8.5% to
Figure 3. Mean (95% CI) anthropometrics among females, adjusted* for age, race, !height, smoking history and diabetes history.
NHANES: National Health and Nutrition Examination Survey ALLRT: AIDS Clinical Trials Group Longitudinal Linked Randomized Trials *Age centered at
40 years; reference for race is white; reference for smoking history is non-smoker; reference for diabetes history is no diabetes history. BMI not
adjusted for !height. a NHANES significantly different from ALLRT (p,0.0001). b Significantly different from 1st time period (p = 0.02). c Significantly
different from 1st time period (p,0.0001). d NHANES significantly different from ALLRT (p = 0.01). e NHANES significantly different from ALLRT
(p = 0.03).
doi:10.1371/journal.pone.0065306.g003
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4.9% of all HIV-related deaths in the US, based on death
certificates [29]. Earlier treatment may contribute to less HIV-
associated wasting, since all HIV-infected are recommended to
start treatment [30]. Between 1995–2005, the NFHL cohort
documented wasting using 3 definitions, one of which was BMI
,20 kg/m2 [27]. These authors noted that 8% of 466 subjects
with 6 months of follow-up had wasting by their BMI criteria. This
is similar to our results, in which 9.4% of HIV-infected subjects
had a BMI ,20 kg/m2. Though wasting may be decreasing
overall in untreated persons with HIV in the US, when defined by
low BMI it may reflect the national trend of increasing body
weight in the US population. Fewer ALLRT and NHANES
participants were below a BMI of 20 kg/m2 in the later time
period.
While less HIV-infected individuals may be affected by wasting,
extremely high body weight may adversely affect health. Crum-
Cianflone, et al. analyzed a large US military HIV cohort and
noted that after starting ART, obese and underweight subjects had
smaller gains in CD4 T-cell count relative to subjects with normal
or overweight BMI [15]. HIV-infected patients in the obese BMI
range at an outpatient clinic in Tennessee also had less CD4 T-cell
count gain over the first 12 months of ART, compared to
overweight patients (p = 0.03) [16]. HIV-infected subjects starting
ART may especially be at a health disadvantage if underweight, or
obese.
Our results indicate that WC prior to ART is smaller in both
men and women when compared to a HIV-uninfected cohort.
Waist circumferences have been measured in some other studies
involving HIV-infected subjects naı¨ve to ART. Visnegarwala,
et al. documented a smaller mean WC between 1999 and 2002, in
a cohort (n = 422) with more advanced HIV disease and lower
CD4 lymphocyte counts than ALLRT [31]. Mean WC was
reported by race and sex, and ranged from 83.8–88.4 cm for
males and 78.7–88.9 cm for females, which are below our mean
values of 90.9 cm for males and 92.4 cm for females in the 1998–
2002 ALLRT time period. The percentage of non-white subjects
in this study (66.4–96.7% non-white versus 55–57% in ALLRT)
may contribute to differences in the results, since Non-Hispanic
Black and Mexican-American males generally have smaller WC
[32]. In the general U.S. population, large WC is reported to be a
predictor of mortality, as was seen in the Cancer Prevention Study
II Nutrition Cohort [2], and the NIH-AARP study [33]. In HIV-
infected individuals, a relationship between large WC and
mortality has also been reported. After 5 years of follow-up in
the FRAM study, increased WC at baseline was significantly
associated with mortality in multivariate models. However, these
subjects were largely taking ART (over 80% reported current use)
and had higher CD4 cell counts (333–419 cells/mm3) than our
cohort [10]. In a cross-sectional analysis of 666 HIV-infected and
242 HIV-uninfected individuals in the FRAM study, larger WC
was found to correlate significantly with insulin resistance and
HDL-cholesterol [34]. Waist circumferences in untreated HIV
infection, while still smaller than the general US population,
appear to carry similar risk for mortality and metabolic
disturbances.
Arm circumference, as a fat-free mass indicator, may also be an
important indicator of mortality. In both the NHANES I and II
longitudinal studies [35], and the European cohorts of the Seven
Countries Study [36], larger AC predicted lower all-cause
mortality after 14.6, 12.9, and 40 years, respectively. Additionally,
the FRAM study recently analyzed 5-year follow-up anthropo-
metric data in their HIV-infected cohort, over 80% of which were
taking ART. Their results concluded that lower mid-arm muscle
circumference at baseline predicted higher mortality in a
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multivariate model that included traditional CVD and HIV-
related factors [10]. The smaller AC found in our untreated HIV-
infected cohort suggest these individuals may have a greater risk of
death.
Thigh circumferences in females with untreated HIV aren’t
widely described in the literature; however reports describe smaller
values than the HIV-uninfected subjects in our study. In the
Women’s Interagency HIV Study (WIHS), 734 HIV-infected
women on stavudine had a mean TC 4 cm smaller compared to
698 HIV-uninfected controls (p,0.01) at baseline visits between
1999–2005 [37]. Analysis of the Multicenter AIDS Cohort Study
(MACS) showed that ART naive HIV-infected males had a 2 cm
smaller mean TC than HIV-uninfected controls in 1999 [38].
Smaller TC may be associated with a higher risk of CVD and total
mortality, as seen in the MONICA prospective study of
2816 HIV-uninfected adults in Denmark [39]. They reported
increased risk of mortality after 12.5 years of follow-up in persons
below the median TC (55 cm for males and 55.5 cm for females).
Similarly for HIV-infected persons, the FRAM study has
documented increased CVD risk for low leg subcutaneous fat, as
well as increased 5-year mortality for decreased leg muscle mass
[10,40]. Thus, the smaller TC in our HIV-infected subjects in
ALLRT may be associated with higher risk for poor health
outcomes.
Our study has limitations, notably the inability to discern
between different types of tissue in the areas measured. However, a
sub-study of one trial included in the present study, ACTG 384,
noted significant correlation between body circumferences and
DXA measurements prior to, as well as 64 weeks after starting
ART [8]. Additionally, the Abacavir versus d4T Plus Efavirenz
(ABCDE) study in Spain determined that the percent of limb fat
loss required to become clinically evident after ART initiation,
based on visual assessment, was 30 percent [41]. Therefore, while
the change in circumferences correlate to those seen through
imaging, circumference changes likely are not as sensitive a metric
and represent large changes in body tissue volume. Information on
health habits other than smoking, such as diet and exercise is also
unavailable in the ALLRT study. While improvements in exercise
will affect anthropometrics positively in HIV-infected persons [42],
dietary alterations may have little effect [43], though small studies
have found benefits from adherence to a Mediterranean diet
[44,45]. Last, ALLRT was composed of research study partici-
pants, which may affect the generalizability of our findings.
However, participation in ALLRT may minimize the differences
from the general U.S. population, since participants may have had
better overall health than other HIV-infected persons.
In summary, these data demonstrate that differences in
anthropometrics between HIV-infected subjects in ALLRT and
HIV-uninfected subjects in NHANES exist prior to ART and are
statistically and clinically significant. Studies using DXA and MRI
have demonstrated associations between tissue distribution and
HIV disease. Anthropometrics are a simpler, more clinically
feasible method to quantify body changes that can be easily
visualized by both patient and medical care providers. Additional
studies are needed in this HIV-infected cohort to examine the
associations between anthropometrics and future disease risk in
HIV infection.
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